DuPont's once-daily Sustiva filed in USA

8 April 2001

DuPont Pharmaceuticals has submitted a New Drug Application to the USFood and Drug Administration for 600mg and 300mg tablet formulations of its anti-HIV drug, Sustiva (efavirenz), as a once-daily non-nucleoside reverse transcriptase inhibitor.

The firm notes that the new form may help patients better adhere to their anti-HIV treatment as only one tablet per day is required, compared to three capsules a day for the current formulation of the drug. Studies comparing directly-observed therapy to self-administered therapy showed that the latter, with a regimen containing Sustiva plus NRTIs, was almost as effective. DuPont hopes to launch the new formulations in early 2002, but will continue to manufacture the existing 200mg immediate-release capsules for those who prefer them.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight